Study: EGFR Protects Cancer Cells
Posted on: Tuesday, 6 May 2008, 15:00 CDT
U.S. medical scientists say they've discovered a growth factor receptor long known to fuel cancer cell growth, also protects tumor cells.
Researchers at The University of Texas M. D. Anderson Cancer Center said they determined the epidermal growth factor receptor, or EGFR, stabilizes another cell membrane protein that channels a constant supply of glucose to cancer cells, saving them from devouring themselves.
They said their findings might explain why some drugs that block EGFR's activation by its tyrosine kinase activity target have had only limited success.
We show that the receptor is active independent of its kinase activity, Professor Isaiah Fidler said. Up until now everyone -- including us -- focused on kinase, kinase, kinase.
The team showed EGFR binds to another cell membrane protein called the sodium/glucose co-transporter, or SGLT1, protecting SGLT1 from destruction by the cell's proteasome complex.
This complex stabilizes SGLT1 so it continues to transport glucose from the cell membrane into the cell, Professor Mien-Chie Hung said.
The study that included Zhang Weihua, Rachel Tsan, Qiuyu Wu, Wei-Chien Huang and Chao-Hwa Chiu appears in the journal Cancer Cell.
Source: United Press International
Related Articles
- Newly Appreciated Membrane Estrogen Receptor Important Therapeutic Target For Breast Cancer
- Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non-Small-Cell Lung Cancer Drug Market to Nearly Triple to Almost $10 Billion in 2018
- ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
- Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 As First-Line Therapy for Non-Small Cell Lung Cancer
- View Scientific Rationale for Novel Therapeutics in Lung Cancer, And the Results of Clinical Trials to Date Inside 'Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents'
- OSI Pharmaceuticals Launches Study of Tarceva(R) As Adjuvant Treatment for Non-Small Cell Lung Cancer
- Hana Biosciences Announces Positive Interim Results From a Phase I Trial of Talotrexin (PT-523) in Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
- Pivotal Phase III Tarceva Study Published in the New England Journal of Medicine Showed Survival Improvement in Advanced Non-Small Cell Lung Cancer
- OSI Pharmaceuticals Announces Tarceva Granted Approval in Canada for the Treatment of Advanced Non-Small Cell Lung Cancer
- FDA Approves Tarceva-TM- For Patients With Advanced Non-Small Cell Lung Cancer; Only Targeted EGFR Therapy Shown to Improve Survival in Advanced Non-Small Cell Lung Cancer
 |
 |
User Comments (0)
RSS Feeds